← All trials
NCT06964009
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 22, 2025
- Primary completion
- Dec 30, 2026
- Completion date
- Dec 30, 2027
- First posted
- May 9, 2025
- Last posted
- Sep 25, 2025
- Enrollment
- 30
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Harvard UniversityLead sponsor
- Harvard UniversitySponsor investigator
- American Society of Clinical OncologyCollaborator
- Harvard UniversityOfficial
- Department of DefenseCollaborator
- Dialectic Therapeutics, IncCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.